Management appear to be willing to go down the same route as GJT, presuming they complete the transaction. Hold both shares, more AJA now than GJT, larger upside in AJA and transaction not as priced in as GJT.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025